Umarani Pugazhenthi

Umarani Pugazhenthi

Auto-generated profile, based on publicly available information

Umarani Pugazhenthi

Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
HHHannah M. Hicks
Hannah M. Hicks
NPNikita Pozdeyev
Nikita Pozdeyev
SSSharon B. Sams
Sharon B. Sams
UPUmarani Pugazhenthi
Umarani Pugazhenthi
EBElise S. Bales
Elise S. Bales
RSRebecca E Schweppe
Rebecca E Schweppe
Mutations in BRAF are common in advanced papillary and anaplastic thyroid cancer (PTC and ATC). However, patients with BRAF-mutant PTC currently lack therapies targeting this pathway. Despite the approved combination of BRAF and MEK1/2 inhibition for patients with BRAF-mutant ATC, these patients often progress. Thus, we screened a panel of BRAF-mutant thyroid cancer cell lines to identify new therapeutic strategies. We showed that thyroid cancer cells resistant to BRAF inhibition (BRAFi) exhibit an increase in invasion and a proinvasive secretome in response to BRAFi. Using reverse-phase protein array (RPPA), we identified a nearly 2-fold increase in expression of the extracellular matrix protein, fibronectin, in response to BRAFi treatment, and a corresponding 1.8- to 3.0-fold increase in fibronectin secretion. Accordingly, the addition of exogenous fibronectin phenocopied the BRAFi-induced increase in invasion while depletion of fibronectin in resistant cells resulted in loss of increased invasion. We further showed that BRAFi-induced invasion can be blocked by inhibition of ERK1/2. In a BRAFi-resistant patient-derived xenograft model, we found that dual inhibition of BRAF and ERK1/2 slowed tumor growth and decreased circulating fibronectin. Using RNA sequencing, we identified EGR1 as a top downregulated gene in response to combined BRAF/ERK1/2 inhibition, and we further showed that EGR1 is necessary for a BRAFi-induced increase in invasion and for induction of fibronectin in response to BRAFi. Implications: Together, these data show that increased invasion represents a new mechanism of resistance to BRAF inhibition in thyroid cancer that can be targeted with an ERK1/2 inhibitor.

14 June 2023
Verified
Other
Open access
HHHannah M. Hicks
Hannah M. Hicks
NPNikita Pozdeyev
Nikita Pozdeyev
SSSharon B. Sams
Sharon B. Sams
UPUmarani Pugazhenthi
Umarani Pugazhenthi
EBElise S. Bales
Elise S. Bales
RSRebecca E Schweppe
Rebecca E Schweppe
Table S1. Thyroid cancer cell lines and their sensitivity/resistance to BRAFi.

14 June 2023
Verified
Other
Open access
HHHannah M. Hicks
Hannah M. Hicks
NPNikita Pozdeyev
Nikita Pozdeyev
SSSharon B. Sams
Sharon B. Sams
UPUmarani Pugazhenthi
Umarani Pugazhenthi
EBElise S. Bales
Elise S. Bales
RSRebecca E Schweppe
Rebecca E Schweppe
Table S2. NormLinear: provides normalized RPPA data in linear values.

14 June 2023
Verified
Other
Open access
HHHannah M. Hicks
Hannah M. Hicks
NPNikita Pozdeyev
Nikita Pozdeyev
SSSharon B. Sams
Sharon B. Sams
UPUmarani Pugazhenthi
Umarani Pugazhenthi
EBElise S. Bales
Elise S. Bales
RSRebecca E Schweppe
Rebecca E Schweppe
Figure S2. BRAF inhibition increases fibronectin expression and secretion, which is blocked by ERK1/2 inhibition.

14 June 2023
Verified
Other
Open access
HHHannah M. Hicks
Hannah M. Hicks
NPNikita Pozdeyev
Nikita Pozdeyev
SSSharon B. Sams
Sharon B. Sams
UPUmarani Pugazhenthi
Umarani Pugazhenthi
EBElise S. Bales
Elise S. Bales
RSRebecca E Schweppe
Rebecca E Schweppe
Figure S6. The ERK1/2 inhibitors SCH772984 and Ulixertinib have similar effects on cell viability in vitro.

14 June 2023
Verified
Other
Open access
HHHannah M. Hicks
Hannah M. Hicks
NPNikita Pozdeyev
Nikita Pozdeyev
SSSharon B. Sams
Sharon B. Sams
UPUmarani Pugazhenthi
Umarani Pugazhenthi
EBElise S. Bales
Elise S. Bales
RSRebecca E Schweppe
Rebecca E Schweppe
Figure S3. Sensitivity to BRAF inhibition does not correlate with fibronectin, α5β1 integrin, c-MET, or FAK/Src levels. BRAF inhibition increases fibronectin expression and secretion, which is blocked by ERK1/2 inhibition.